Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... All patients received a dose of 234 mg on
day 1 in the deltoid muscle. From
day 8 and monthly thereafter, patients were assigned ... muscle one week apart (Day 1 at 234 mg and
day 8 at 156 mg), followed by injections every month ...
Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
... events than patients given edoxaban twice a
day (BID). The analysis finds that bleeding ... curve or AUC). Delivering a compound twice per
day generally allows for more consistent ... dosing and one to three hours post-dosing on
day 28. The relationship between PK and all bleeding ...
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
... endpoint is the treatment failure rate at Study
day 80. This endpoint was successfully measured as a ... endpoint of the 'treatment failure rate at Study
day 80,' we expect to replicate statistical ... namely median time-to-treatment failure through
day 50 (p-value 0.1177), orBec(R) did achieve ...
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
... received low-dose bromfenac bilaterally twice a
day for 42 days. Patient baseline scores were ... bromfenac and were compared to baseline at
day 14,
day 42 ...
Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
... - Improvement Was Noted At
day 3 And All Subsequent Study Visits -
FORT ... assessments at all study visits starting at
day 3. In addition, lurasidone was generally ... arms. Patients remained in the hospital until the
day 28 assessment after which patients could be ...
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
... dose of ANX-514 was a secondary objective. On
day 1, patients were dosed with either ANX-514 or Taxotere and, on
day 22, were dosed with the other drug. Patients ... with corticosteroids prior to treatment on
day 1 and ...
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
... log10 reduction in viral load). Viral load at
day 4 (12 hours after the last dose) was compared to ... and the engagement of clinical sites.
14
day Healthy Volunteer Study
Anadys recently ... mg bid). Subjects received ANA598 or placebo on
day one followed by pharmacokinetic assessment over ...
Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
... PI plasma concentration levels. After a 7
day washout
period, subjects were randomized to 15 ... mg, 50 mg, or 200
mg) once daily or placebo. On
day 15, subjects also received, once again,
either ... with the final dose of
SPI-452. On
day 16 subjects received darunavir, atazanavir or ...
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
... either ecabet sodium or placebo four times per
day for 43 days. The object of the study was to ... Schirmer Test score was seen as early as
day 22 of treatment and continued to trend upwards through
day 43. Adverse events were uncommon and similar ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
... mg/m2 followed by docetaxel
60 mg/m2 on the first
day of every 21-day cycle; or docetaxel 75 mg/m2 on the
first
day of every 21-day cycle. Treatment continued until ... reactions have resolved within several hours to a
day once the
infusion is terminated. In some ...
Pharmasset Reports Fiscal Year End 2008 Financial Results
... covering R7128.
Results from the 28
day study were presented at the recent ... 2009
-- Report end of treatment data from 28
day add-on study with R7128 in
non-responder, ... -- Report end of treatment results from 28
day add-on study with R7128 in
treatment ...
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
... dosed intravenously at 300 mg and 450 mg twice a
day to patients with cSSSI for 5 to 14 days, as ... of chronic bronchitis (ABECB). A 200 mg once a
day dose of delafloxacin for 5 days was shown to be as efficacious as a 500 mg once a
day dose for 7 days of levofloxacin.
About ...
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
... placebo group. Treatment was started on the first
day of the current cycle of chemotherapy and was ... infusion, just after the infusion, and then every
day for five days to ensure that the reversibility ... pulmonary embolism, and all-cause mortality up to
day 17. The main safety endpoint was major bleeding ...
Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
... (75 mg/m^2), and TBI (1320 cGy), followed one
day later by an infusion of one unit of non-cultured ... early engraftment, the engrafted cells present at
day seven were derived almost entirely from the ... at 180 days post-transplant. One patient died on
day 462 from a rare complication of myelitis ...
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
... endpoint of elimination of ocular pain one
day post surgery.
When considered ... Xibrom once daily or placebo. Dosing began one
day before cataract surgery and continued for 14 days ... of patients experiencing no pain was assessed at
day 1 post surgery, and the proportion of patients ...
Micromet Expands Committed Equity Financing Facility to $75 Million
... closing price of the common stock on the trading
day prior to the draw down notice, in each case ... provided that if the average market price on any
day during the pricing period is less than the greater of $2.00 or 85% of the closing price of the
day preceding the ...
Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts
... & Gender Equity:
WHAT: World AIDS
day Audio Media Conference
WHEN:
... are calling on the United States this World AIDS
day to prioritize effective prevention alongside ... faiths and beliefs will gather for a World AIDS
day Interfaith Service in Washington, D.C. This ...
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
... as
effective as Pred Forte dosed eight times a
day in treating uveitis.
Durezol was also safe and ... equal to
1 cell) than did the Pred Forte group at
day 14 (69% vs. 62%,
respectively). This trend continued through
day 42.
Pain/ocular discomfort was assessed using a ...
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
... discontinuations during this 28
day treatment period.
The most common adverse ... Mean reductions of HCV RNA from baseline to
day seven with TMC435 alone
and in triple therapy ... achieved undetectable HCV RNA (<10 IU/mL) at
day 28
(RVR=89 percent).
"These data provide ...
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
... with radezolid at a dosage of 450 mg once a
day (38/39);
94.4% for patients treated with radezolid 450 mg twice a
day (36/39); and
97.4% for patients treated with linezolid 600 mg twice a
day (37/38).
Clinical cure rates among clinically ...
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
... patients took either tonabersat or
placebo once a
day for a three-month period after which the ... and vice versa. The tonabersat dosage was 20mg a
day for the first
two weeks, increasing to 40mg a
day for the subsequent 10 weeks.
In line with ...
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
... steroid that can be used
effectively four times a
day to reduce inflammation in patients with
moderate ... equal to
1 cell) than did the Pred Forte group at
day 14 (69% vs 62%, respectively).
This trend continued through
day 42.
Ocular discomfort and pain is a ...
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
... inflammation in which
treatment was initiated one
day prior to surgery. The multicenter,
randomized, ... and
relieving ocular pain/discomfort as early as
day 3/4."
A significantly greater percentage of ... to 5
anterior chamber cells and no flare) by
day 14: 81.3% of the Durezol
treated patients in the ...
Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
... pain between Ketotransdel(TM) and
placebo at
day 3. This endpoint is measured by using the Visual ... and other efficacy
parameters measured by VAS at
day 3 and
day 7. In addition to evaluating
for efficacy and ...
Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
... twice and Enbrel was
administered either every
day for the first 14 days (for the histopathology
and immunology studies) or every other
day over the entire study period of
28 days (for the ... Dr.
Zimmerman. "I hope that CEL-2000 will some
day be used to lessen the damage
caused by rheumatoid ...
Soyfoods Do Not Impact Sperm Count
... soyfoods as
less than 3 ounces of a beverage per
day -- about one 8 ounce glass of a
beverage every ... sperm/cc seminal fluid) is highly
variable from
day to
day and seasonally in all men. This is most clear ...
New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
... results suggest that four to five cups of tea a
day may improve
attention and focus. This and other ... equal to about two
to four cups of green tea per
day was provided to animals with induced
Parkinsonism ... that drinking three or more cups of tea per
day delayed motor
symptoms by 7.7 years. In addition ...
Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
... four-fold increase from baseline HI titers. By
day 56, at least 50% and
up to 67% of evaluable ... HI titers of
40 or more in 44% of subjects by
day 56.
Even at the lowest dose tested (0.033 mg H5 DNA), one of the six
subjects was a responder by
day 56. Some subjects who received the highest
H5 DNA ...
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
... with Parkinson's
disease by 2.1 hours per
day on average, compared to baseline.
Specifically, ... reduced "off"
time by an average of 2.1 hours per
day from baseline, compared to a
reduction of 0.4 hours per
day for placebo.
Once-daily use of Requip XL was ...
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
... at 28
days after completion of dosing, which was
day 56 of the study. Pulmonary
function (FEV1) ... (p=0.009) increase compared to placebo, at
day 56.
Arikace was well tolerated, with no ... infection. The
ability to deliver a drug once a
day that may penetrate the CF biofilm and
achieve a ...
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
... side effects. Importantly,
the 30
day all-cause mortality, one of the secondary ... clofarabine
administered as 30mg/m2 per
day for five consecutive days then, based on
their ... cycles of treatment at a
dose of 20 mg/m2 per
day for five consecutive days.
Significant Unmet ...
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
... mg/m2 on days 1, 4, 8, 11, DOXIL at 30
mg/m2 on
day 4 and dexamethasone at 40 mg on days 1 through 4, ... 1 through 21 plus prednisone at 50 mg every other
day for
four, 28-day LP cycles. This was followed by ... dexamethasone at 40 or 20 mg on the day
of and
day after each VELCADE dose. Patients were treated ...
GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
... IV/oral dose regimen
(90mg IV and OND on
day one and 50mg tablets on days two and three) ... oral casopitant
doses (a single 150mg tablet on
day one, or a 150mg tablet on
day one
followed by 50mg on days two and three) and ...
International Symposium on Malignant Mesothelioma 2008
... and
terminal effects of this tragic cancer.
day 1: Advocacy, Thursday, June 26 is a rallying cry ... impressive and prestigious group of panelists for
day 2:
Science, Friday, June 27.
A Gala Dinner will ... a personal
perspective as a featured speaker.
day 3: Community, Saturday, June 28, will be devoted ...
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
... and placebo groups and challenged three times a
day with
gluten or gluten placebo during a 14
day period. Four doses of the oral
formulation of ... the prevention of increase in LAMA ratio from
day 0 ...
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
... design study. COPD patients entered a 7-14
day run-in period
during which subjects received ... following the first dose
of study medication at
day 1 was statistically significantly improved in
the ... (SGRQ), the results of which were similar at
day 1 and did
not change markedly over the six weeks ...
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
... the first dose of study
medication and the first
day of symptom resolution (rectal bleeding ... the first
dose of study medication and the first
day of three consecutive days of
symptom resolution. ... resolution of rectal bleeding at the first
day and first of three days, respectively: ...
Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being
... 0.015 mg of ethinyl
estradiol (an estrogen), per
day over a twenty-one
day period of use.
NUVARING has an outer diameter ... the ring is
removed three weeks later on the same
day of the week as it was inserted
and at about the ...
Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
... by a single retrospective "recall" report at
day 28, was not
met. However, an assessment of ... scale (VAS) measurements 12 hours after
dosing at
day 7 and
day 28 revealed significant improvement in the ...
Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
... their quality of life."
At the end of the first
day of treatment, the Aguilar's were starting
to ... close to being pain
free just after the first
day of treatment. The following morning ... regenerative process.
After the third and final
day of their treatment the Aguilars' were
true ...